|Bid||18.35 x 1000|
|Ask||18.79 x 2200|
|Day's range||18.04 - 18.52|
|52-week range||18.04 - 34.73|
|Beta (5Y monthly)||1.10|
|PE ratio (TTM)||N/A|
|Earnings date||24 Oct 2023 - 30 Oct 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||29.39|
Share prices of direct-to-consumer healthcare company Hims & Hers Health (NYSE: HIMS) started hot in 2023, doubling from $6 per share to $12. Here is why this stock is an opportunity you don't want to miss. Hims & Hers is a digital healthcare platform where patients can consult professionals for several conditions and receive personalized scripts sent to their homes.
Teladoc (TDOC) closed the most recent trading day at $18.43, moving -0.86% from the previous trading session.
The company's current lineup includes the t:slim X2 and the newly cleared Mobi Insulin Pump, which management calls "the world's smallest durable insulin delivery system." Despite this progress on the regulatory front, Tandem has been bruised and battered on the stock market over the past year, as its financial results haven't been as good. The company's sales of insulin pumps have declined amid the challenging economy, leading to lower year-over-year revenue growth.